Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03633110
Title Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Genocea Biosciences, Inc.
Indications

renal cell carcinoma

transitional cell carcinoma

head and neck squamous cell carcinoma

melanoma

lung non-small cell carcinoma

Therapies

GEN-009

GEN-009 + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.